Psoriasis still itching and burning after two months of creams: will UVB work faster, and who should have phototherapy?

Short answer

Psoriasis that still itches and burns after creams or pills is not a promise that light will work faster. Narrowband UVB is an option when creams do not control it. Light does not end the disease. Ask about joints, and do not use a tanning bed.

Two months of itch is not a ranking that light is faster

A photo does not grade the disease, and it does not show that light will be faster than the medicine already in use. The AAD treatment page, updated 22 May 2026, says there is no single best treatment and no treatment works for everyone. The goals are to ease itch, remove scale and clear the skin, treat nail changes if present, and reduce joint pain if psoriatic arthritis is present.

Most people treat psoriasis with medicine applied to the skin. Mild disease is often treated with that alone. In more extensive disease, a topical medicine may sit beside light or a medicine that works through the body, such as methotrexate or a biologic. The page on a painful burning rash, shingles or psoriasis, answers a different question about naming the rash.

NICE recommendation 1.3.1.6 asks for a review 4 weeks after a new topical treatment in adults. If there is little or no improvement, the next option is discussed. Two months of itch and burning is a reason to revisit severity, how the medicine was used, and the next step. It is not evidence that light is faster than creams for every person.

Who the opened guidance mentions for narrowband UVB

NICE recommendation 1.4.1.1, dated 2012, says to offer narrowband UVB to people with plaque or guttate psoriasis that cannot be controlled with topical treatment alone. It can be given 3 or 2 times a week, depending on preference, and people should be told that a response may be achieved more quickly with treatment 3 times a week. That sentence compares frequencies of light. It does not say light is faster than creams for everyone.

Recommendation 1.3.1.2 says phototherapy, conventional systemic treatment, or targeted immunomodulatory treatment may be offered at the same time when topical treatment alone is unlikely to control the disease, for example when more than 10% of the body surface is affected, when the static Physician’s Global Assessment is at least moderate, or when topical treatment is ineffective, such as in nail disease. More than 10% is an example of extensive disease, not the only door to the next step.

The AAD phototherapy page, opened the same day and without a review date on the page that was retrieved, says research shows different types of phototherapy can treat small areas of stubborn thick plaque, long-standing psoriasis of the hands and feet, plaque that covers a large amount of skin, nail psoriasis, and scalp psoriasis. Most people with psoriasis can use narrowband UVB, including children, people who are pregnant or breastfeeding, and people with a weakened immune system or an ongoing infection. That sentence sits apart from the list of people for whom phototherapy is not recommended.

The excimer laser is a form of narrowband UVB aimed at one area. The AAD says it can treat the scalp, ears, armpits, groin, buttocks, elbows, and knees. That fits limited plaques. It is not an order for every widespread rash to enter a whole-body cabinet, and it is not an order for widespread disease to use a spot treatment only.

Visits per week, and weeks of treatment, are not one number

The AAD says that to be effective, most patients need two or three treatments a week for several weeks. Some need five a week. A dermatologist usually checks after a certain number of treatments, often four to six at the start. That number is a checkup, not a promise that the rash will clear. Research cited on that page says steady improvement is seen when phototherapy is given two to five times a week. Missing more than two appointments should be told to the dermatologist, and missed visits make it unlikely that phototherapy will help.

The Leeds Teaching Hospitals narrowband UVB leaflet, opened 31 October 2026, describes a different centre. People usually attend three times a week. The length of the course varies. An average for psoriasis would be nine weeks. Average is an example from that centre, not a promise that every person finishes in nine weeks. The first exposure is based on test doses on a small area of skin, read 24 hours later, then increased according to the skin’s reaction.

During the course, Leeds says to use the topical treatment the supervising doctor advises, and not to sunbathe or use a sunbed. On treatment days, avoid significant direct sunlight. The AAD treatment page says, separately, that a tanning bed or lying in the sun can burn the skin, which can worsen psoriasis, and that ultraviolet light from the sun or tanning beds can also cause skin cancer over time. Medical light is given under a dermatologist. It is not home sunbathing.

The AAD says that if hospital phototherapy works, a dermatologist may prescribe a home light box or handheld device. That is a prescription, not a tanning salon. NICE says phototherapy is not used routinely as maintenance to control the disease.

Burn, eyes, light-sensitive medicines, and skin cancer

The AAD says the skin should be a little red or pink after each treatment. That is wanted, and it is not counted as a side effect. Effects that can happen straight away include a sunburn-like reaction, mild stinging, dark spots that are more common in medium to dark skin, itching, blisters, which are uncommon, and a burn, which is uncommon. Longer-term effects can include freckles, early skin aging, and a higher chance of skin cancer. Care by a dermatologist is how those longer-term effects are managed.

The AAD does not recommend phototherapy for anyone who has had a melanoma or another skin cancer, a condition that makes skin cancer more likely such as Gorlin syndrome or xeroderma pigmentosum, a condition that makes the skin sensitive to ultraviolet light such as lupus or porphyria, or a medicine that increases ultraviolet sensitivity such as some antibiotics, diuretics, and antifungals. The full medicine list goes to the phototherapy team.

Leeds asks for goggles or a visor. If the eyelids need treatment and goggles are not worn, the eyes must stay completely closed. Male patients wear genital protection. Without eye protection there is a risk of a burn to the eyes and of cataracts later. The same leaflet says that UVB used over many years may age the skin and increase the risk of skin cancer. The risk is very slight at first and increases significantly after about 500 treatments, so a course is not usually recommended more often than once a year. Five hundred is a cumulative line in that leaflet, not a quota to finish.

The NICE public phototherapy page, last updated 1 October 2012, says ultraviolet exposure during phototherapy can increase the risk of skin cancer, so treatment is monitored. Before PUVA, other options are discussed, and the cancer risk is explained as rising with the number of treatments. PUVA is not offered to everyone.

The AAD says not to apply salicylic acid before a session, because it can make UVB less effective. Leeds says to keep using prescribed creams, and not to put cosmetics, perfume, or tanning cream on the skin before treatment, and not to drink alcohol before the cabinet.

When a systemic medicine or a targeted medicine is discussed

NICE recommendation 1.4.1.2 says to offer another second- or third-line treatment when narrowband UVB gives an unsatisfactory response or is poorly tolerated, when disease relapses rapidly, defined as greater than 50% of the baseline severity within 3 months, when travel or time off work makes attendance difficult, or when the skin-cancer risk is especially high.

Recommendation 1.5.2.1 offers conventional systemic treatment when topical treatment cannot control the disease, the impact on physical, psychological, or social wellbeing is significant, and at least one of the following applies. The psoriasis is extensive, for example more than 10% of the body surface or a PASI score of more than 10. Or it is localised but causes significant functional impairment or high distress, for example severe nail disease or a high-impact site. Or phototherapy has been ineffective, cannot be used, or has led to rapid relapse as defined above. That decision belongs in a specialist setting. It is not a home score from a photograph.

For people who meet that bar, NICE offers methotrexate as the first-choice conventional systemic treatment, except in stated situations. Ciclosporin is the first choice when rapid or short-term control is needed, such as a flare, when there is palmoplantar pustulosis, or when conception is being considered by either partner and a conventional systemic medicine cannot be avoided. Acitretin is considered in adults when methotrexate and ciclosporin are not appropriate or have failed. This page does not print doses. The dose is a clinician’s decision.

The AAD lists medicines that work through the body and are approved for psoriasis, including apremilast for plaque psoriasis and psoriatic arthritis, cyclosporine for extensive or disabling disease, methotrexate for severe disabling disease, and acitretin for severe disease without immune suppression. People who are pregnant or planning pregnancy should not take acitretin. The AAD page says not to drink alcohol while taking methotrexate. NICE says, in a separate sentence, that liver risk is assessed before and during methotrexate, including alcohol use, obesity, and diabetes.

Targeted immunomodulatory treatment is started and supervised only by a consultant dermatologist experienced in psoriasis. For adults with plaque psoriasis, NICE technology appraisals apply when the PASI score is 10 or more and the DLQI is more than 10, after conventional systemic treatment and phototherapy have failed, are contraindicated, or are not tolerated. Infliximab uses a different bar: a PASI score of 20 or more and a DLQI of more than 18. Those two bars stay apart. They are not numbers for a reader to calculate from a photo. If psoriasis and joint disease are both present, changes to these medicines are planned with a rheumatologist.

Do not stop a medicine a clinician prescribed, including a steroid taken by mouth or injection. Changes belong to the clinician.

Surface area is not the only measure, and joints are asked about in everyone

NICE asks that the record include body surface area, nails, and high-impact or difficult sites such as the face, scalp, palms, soles, flexures, and genitals, even when the surface area is not high. Itch, burning, and lost sleep belong in the impact questions. Recommendation 1.2.1.10 refers to a dermatologist when the diagnosis is uncertain, the disease is severe or extensive, topical treatment cannot control it, acute guttate psoriasis needs phototherapy, nail disease has a major functional or cosmetic impact, or the disease has a major effect on wellbeing.

Recommendation 1.2.2.1 offers a yearly assessment for psoriatic arthritis in any type of psoriasis, especially important in the first 10 years after onset. Recommendation 1.2.2.2 uses a tool such as PEST in adults, and says PEST does not detect axial disease or inflammatory back pain. Suspected psoriatic arthritis is referred to a rheumatologist.

The AAD symptoms page says joint disease is more likely when psoriasis is severe. Most people notice skin disease years before the joints. Joint disease before the skin is less common. Early signs include a swollen tender joint, especially a finger or toe, heel pain, swelling just above the heel, and morning stiffness that fades during the day. That page says psoriatic arthritis cannot be ended by treatment. Treatment can keep it from becoming disabling. Nail changes on that page are a skin sign of psoriasis, seen at some point in about half of people with plaque psoriasis. That is a group figure, not a diagnosis of joint disease.

Plaque psoriasis develops in about 80% to 90% of people who have psoriasis. That is a group figure, not the type of one photographed rash. On darker skin, the AAD says plaques tend to be thicker and more scaly. NICE says redness may be underestimated in Fitzpatrick skin types 5 and 6.

Creams, light, systemic medicines, and targeted medicines

What to ask next

Questions to answer for the clinician

1. How many months or years has the rash been present?
2. About what share of the skin surface is involved?
3. Are the scalp, genitals, palms, or soles involved?
4. How severe is the itch?
5. How severe is the burning or pain?
6. Does it disturb sleep?
7. Which topical steroid is in use?
8. How long has it been used, and were there breaks?
9. Is a vitamin D analogue in use?
10. Which oral or injected medicine is in use?
11. How did earlier treatment respond?
12. Has UVB been used before?
13. Has there been a severe sunburn?
14. Is there a history of skin cancer?
15. Is a light-sensitising medicine in use?
16. Is narrowband UVB suitable?
17. Would targeted light fit better?
18. If light is used, how many visits a week are planned?
19. After about how many sessions is the first review?
20. Should a cream continue, and which one must not go on before the cabinet?
21. If UVB is not enough, what is next?
22. Do the systemic-treatment criteria apply?
23. Do the targeted-medicine criteria apply?
24. Are blood tests needed before a systemic medicine?
25. Is there a reason to consider psoriatic arthritis?
26. Is there joint pain or morning stiffness?
27. Should the DLQI be used?
28. How will skin-cancer risk be followed?
29. Which symptoms mean coming back before the next visit?

What to bring

• A photo at the worst point, and a photo after treatment
• The names of creams and pills, how long they were used, and side effects
• Itch, burning, and sleep
• Joint symptoms and nail changes
• Earlier phototherapy and any skin-cancer history
• Every medicine, including ones that may increase light sensitivity
• Smoking, alcohol, and infections around a flare, if present
• Earlier blood tests, if any

Mechanism, as summarized by the author

Asst. Prof. Dr. Norawit Raatpiboon lines the opened sources up this way. Psoriasis is skin inflammation with skin cells that divide quickly. Creams reduce inflammation where they are applied. Controlled UVB slows those dividing cells and reduces inflammation. Medicines that work through the body are discussed when the disease is extensive, life is affected, or light is not enough. The choice uses area, site, quality of life, joints, and the response so far. It does not rank light as faster than creams for every person.

Sources opened for this page

• American Academy of Dermatology. Diagnosis and treatment. Updated 22 May 2026
• American Academy of Dermatology. Phototherapy. Opened 31 October 2026
• American Academy of Dermatology. Signs and symptoms. Opened 31 October 2026
• NICE CG153 recommendations. Opened 31 October 2026. Phototherapy statements dated 2012
• NICE public phototherapy page. Last updated 1 October 2012
• Leeds Teaching Hospitals. Narrowband UVB. Opened 31 October 2026

Common questions

What is phototherapy for psoriasis?

The AAD describes light that a dermatologist prescribes, to slow rapidly dividing skin cells, quiet an overactive immune response, reduce inflammation, and reduce itch. It is not sunbathing.

What is narrowband UVB?

Leeds describes a specific band of ultraviolet B, which is part of the sun’s rays, given in hospital under supervision, with the time set from the skin’s reaction.

How do UVB and UVA differ on this page?

Narrowband and broadband UVB are the cabinet or lamp treatments the AAD describes. PUVA is a different option that uses psoralen and then UVA, and it is not offered to everyone.

Does light work faster than creams?

No opened source says it is faster for everyone. NICE says only that, among people receiving narrowband UVB, a response may come more quickly with three sessions a week than with two.

How many sessions until it improves?

There is no promised number. The AAD reviews treatment after about four to six sessions at the start. That is a checkup, not a point at which the rash must clear. Leeds uses a nine-week average at that centre as an example.

How many visits a week?

The AAD says most people need two or three a week, and some need five. Leeds usually uses three. NICE offers three or two. Those three sentences stay apart.

Does light end the disease?

No. NICE says phototherapy is not used as routine long-term control, and that relapse occurs in most people after topical treatment is stopped.

Can the rash return?

Yes. NICE defines rapid relapse after light as greater than 50% of the baseline severity within 3 months, which is a reason to discuss the next treatment.

Can creams continue during light treatment?

Yes, as the clinician directs. Leeds says to keep using prescribed creams. The AAD says not to apply salicylic acid before a session, because it can make UVB less effective.

Does redness after a session mean harm?

The AAD says a little pink or red skin after each session is wanted. Marked redness, severe pain, or a burn should be reported to the treating team. Do not lengthen the time at home.

Is there a skin-cancer risk?

There is a reason to follow it. The AAD lists a higher risk among long-term effects. Leeds says the risk increases significantly after about 500 treatments. NICE asks that this risk be discussed before PUVA.

Can sunlight or a tanning bed replace it?

No. The AAD says sunbathing or a tanning bed can burn the skin and worsen psoriasis. Leeds says not to sunbathe and not to use a sunbed during the course.

Can darker skin receive UVB?

The AAD says most people can use narrowband UVB. Dark spots after treatment are more common in medium to dark skin, and NICE says redness may be underestimated in skin types 5 and 6. The dose starts from a skin test, not from a guessed skin colour.

Who should not have phototherapy?

The AAD does not recommend it after a skin cancer, including melanoma, in ultraviolet-sensitive conditions such as lupus or porphyria, or with medicines that increase ultraviolet sensitivity. That list does not remove children, pregnancy, or a weakened immune system from the separate sentence that most people can use narrowband UVB.

What if UVB is not enough?

NICE moves to another second- or third-line option, including a systemic medicine, when light is not enough, is poorly tolerated, relapse is rapid, attendance is impractical, or the skin-cancer risk is high.

When is a pill considered?

When all three parts of the NICE bar are met: creams do not control it, life is significantly affected, and the disease is extensive, limited but high-impact, or light cannot be used. Starting the medicine belongs in a specialist setting.

When is a targeted medicine considered?

When an experienced dermatologist finds that the adult NICE bar is met, such as a PASI of 10 or more and a DLQI of more than 10 after light and conventional systemic treatment have not worked. Infliximab uses a higher PASI and DLQI bar. Do not calculate this from a photo.

How are psoriasis and joint disease connected?

NICE offers a yearly joint assessment and referral to a rheumatologist when joint disease is suspected. The AAD describes early signs in a finger or toe, the heel, and morning stiffness. A changed nail is not the name of joint disease.

Does two months of itch mean the medicine was wrong?

Not by itself. NICE reviews a new cream at 4 weeks if there is little improvement. The visit should ask about severity, how the medicine was used, and the next step, not conclude that light must be faster.

Which symptoms mean calling 1669?

Call when the person is not already in a hospital and most of the skin is red, or pustules cover most of the skin, together with looking very ill, fever, chills, a rapid pulse, or trouble keeping warm. Itch and burning alone are not that call.

Limit of this page

This page summarizes sources that were opened, so a reader can prepare questions for a dermatologist. It does not grade a rash from a photo, it does not say to sunbathe or use a tanning bed instead of medical light, and it does not say to start or stop a medicine. If an emergency sign is present and the person is not already in a hospital, call 1669.